# Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome

> **NCT02117076** · PHASE4 · TERMINATED · sponsor: **Theresa Zesiewicz, MD** · enrollment: 5 (actual)

## Conditions studied

- Restless Leg Syndrome

## Interventions

- **DRUG:** Gabapentin immediate release
- **DRUG:** Gabapentin enacarbil extended release

## Key facts

- **NCT ID:** NCT02117076
- **Lead sponsor:** Theresa Zesiewicz, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-04
- **Primary completion:** 2016-06
- **Final completion:** 2016-06
- **Target enrollment:** 5 (ACTUAL)
- **Why stopped:** Recruitment unsuccessful due to overly restrictive inclusion/exclusion criteria.
- **Last updated:** 2021-11-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02117076

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02117076, "Blinded, Randomized Study of Gabapentin (Neurontin®) and Gabapentin Enacarbil (Horizant™) in Restless Leg Syndrome". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT02117076. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*